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Context: Low plasma high-density lipoprotein (HDL) cholesterol is a major abnormality in abdom-
inalobesity. This relatesduetoacceleratedHDLcatabolism,but theunderlyingmechanismrequires
further elucidation. The relationships between HDL catabolism and other variables that may be
modified in abdominal obesity, such as very low-density lipoprotein (VLDL) subspecies (VLDL1,
VLDL2) kinetics, liver fat, or visceral adiposity, remain to be investigated.
Objectives:Our aim was to study the associations between HDL apolipoprotein (apo)-A-I fractional
catabolic rate (FCR) and the kinetics of VLDL subspecies and estimates of liver and visceral and sc fat.
Design:Wecarried out amulticenter in vivo kinetic study using stable isotopes (deuterated leucine
and glycerol) in 62 individuals with abdominal obesity.
Results: In a multivariate analysis, among the morphological and biological parameters that may
predict apoA-I FCR, liver fat (  .400, P  .003), and VLDL1-apoB (  .307, P  .020) were
independently associated with apoA-I FCR. In a multivariate analysis, among the kinetic parame-
ters, VLDL1-triglycerides (TGs) indirect FCR (  .357, P  .001), VLDL1-TG production rate ( 
0.213, P .048), and apoA-II FCR ( .667, P .0001) were independently associated with apoA-I
FCR. After adjustment for VLDL1-TG production rate, liver fat was nomore correlatedwith apoA-I
FCR. No association between apoA-I FCR and visceral fat was observed.
Conclusions:We show that VLDL1 is an important independent determinant of apoA-I FCR andmore
precisely that apoA-I FCR is independently associated with both catabolism and the production of
VLDL1-TG. Inaddition,weshowanassociationbetweenliverfatandapoA-IFCRthat ismostlymediated
byVLDL1-TGproduction.Thesedata indicatethat, inabdominalobesity,dysfunctionalVLDL1metabolism
is an important modulator of HDL apoA-I catabolism. (J Clin Endocrinol Metab 99: 4281–4290, 2014)
Abdominal obesity is part of the metabolic syndromeand is strongly associated with insulin resistance,
dyslipidemia, and increased cardiovascular risk (1–4).
Low high-density lipoprotein (HDL) cholesterol is a main
feature of the dyslipidemia associated with abdominal
obesity (5) that has been shown to be amain risk factor for
cardiovascular disease in metabolic syndrome (3, 6). In
vivo kinetic studies performed in abdominally obese in-
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dividuals have shown that low plasma concentration of
HDL cholesterol is the consequence of increased HDL
catabolism (7–9). However, among abdominally obese
subjects, there is a large variability in apolipoprotein
(apo)-A-I fractional catabolic rate (FCR) that requires
investigation.
We have previously shown that HDL-apoA-I catabo-
lism is positively correlated with very low-density lipo-
protein (VLDL)-apoBproduction rate (8).However, some
questions remained unanswered. Indeed, the link between
apoA-I FCR and VLDL subspecies, whose evaluation is
critical to the metabolic syndrome or type 2 diabetes, has
not been studied. Lipoprotein kinetic studies have shown
that VLDL are metabolically heterogeneous, with accu-
mulating evidence demonstrating that both the produc-
tion and catabolism of large triglyceride-rich VLDL1 (Sf
60–400) and smaller cholesterol-rich VLDL2 (Sf 20–60)
are regulated independently of each other (10). The sep-
arate evaluation of VLDL1 and VLDL2 metabolism is im-
portant in themetabolic syndromeor type 2 diabetes, con-
ditions in which the hepatic oversecretion of VLDLs is
mainly due to increased secretion of the triglyceride-rich
VLDL1 particles (11, 12). Thus, it is important to analyze
precisely the kinetic associations between HDL-apoA-I
and both VLDL1 and VLDL2 lipoproteins.
VLDL1 secretion has been shown to be positively cor-
related with liver fat and visceral fat (11). However, liver
fat and visceral fat were not determined in previous ki-
netics studies of HDL-apoA-I, and it is not clear whether
the association between HDL-apoA-I catabolism and the
VLDL (or VLDL1) secretion rate is a direct one or is in-
directly mediated by the extent of ectopic fat in the liver
and visceral/sc regions of the abdomen.
To extend our previous findings on the association be-
tween apoA-I and VLDL kinetics, we investigated in a
relatively large multicenter tracer study the relationships
of apoA-I catabolismwith thekinetics ofVLDLsubspecies
and hepatic, visceral, and sc fat compartments in abdom-
inally obese individuals.
Research Design and Methods
Study cohort
Sixty-two subjects were recruited at three study centers ac-
cording to the following inclusion criteria: men or postmeno-
pausal women, 35–65 years of age, BMI greater than 25 kg/m2
and less than40kg/m2, abdominal obesity according toNational
Cholesterol Education Program/Adult Treatment Panel III
(waist circumference88 cm forwomen and102 cm formen),
and at least one lipid abnormality (plasma triglycerides 1.7
mmol/L and 4.5 mmol/L and/or HDL cholesterol 1.29
mmol/L for women and 1.03 mmol/L for men).
Exclusion criteria were HDL cholesterol below 0.6 mmol/L,
total cholesterol above 6.5 mmol/L or genetic hyperlipidemia,
apoE2/E2 or apoE4/E4 homozygosity, type 2 diabetes treated
with oral agents and/or insulin, a history of cardiovascular dis-
ease, systolic bloodpressure above160mmHgordiastolic blood
pressure above 95 mm Hg, a history of surgical procedures for
weight loss, the presence of any clinically significant endocrine
disease, severe hepatic impairment (aspartate aminotransferase
or alanine aminotransferase greater than 3 times the upper limit
of normal) or renal function (creatinine clearance30mL/min), or
proteinuria (30 mg/dL). Subjects were not allowed any lipid-
lowering drugs, antiobesity drugs, nonselective -blockers, or
agents known to affect lipid metabolism. Individuals with his-
tories of alcohol and/ordrugabuse, current smoking, or smoking
cessation within the past 3 months were also excluded.
Subjectswere advised to followaweight-maintenancediet for
6 weeks before the kinetic studies. Body weight was measured
with participants wearing undergarments or very light clothing
and no shoes. Subjects with greater than 3% variation in weight
during this period were excluded from the study. Waist circum-
ferencewas recorded at themidpoint between the lower ribmar-
gin and the iliac crest. Three consecutive readingswere taken and
the mean was recorded.
Study design
The protocol included three study visits comprising a fasting
kinetic study, determination of intraabdominal fat depots, and a
heparin test on separate dates. The ethics committee at each site
approved the study design and each subject gavewritten informed
consent before participation in the study (trial registered as number
NCT00408148).
Kinetic protocol, isolation of lipoproteins, and
biochemical analyses
The subjects were admitted at 7:30 AM and baseline blood
samples for the kinetic study and biomarkers (apoA-I, apoA-II,
apoB, apoCIII, apoE, lipoproteinA (LpA)-I, glucose, insulin, and
LDL particle size) were taken. At 8:00 AM, a bolus injection of
[1,1,2,3,3-2H5]glycerol (500mg) and [5,5,5-
2H3]leucine (7mg/kg)
was given and blood drawn as previously described (13). Isolation
ofVLDL1andVLDL2andmeasurementsof isotopic enrichmentof
leucine in apoB and glycerol in triglycerideswere performed as pre-
viously described (13). Total apoB and triglyceride content in
VLDL1andVLDL2weredeterminedat0,4,and8hoursafter tracer
injection. Biochemical analyseswere performed andLDLpeak size
was measured as previously described (14).
Isolation of apolipoproteins and glycerol:
measurement of isotopic enrichment
VLDL1 and VLDL2 were isolated from plasma as previously
reported (13). HDL-apoA-I and HDL-apoA-II were isolated
from plasma by sequential ultracentrifugation, separated by
SDS-PAGE, and blotted on to a polyvinylidene fluoride mem-
brane. ApoB (isolated from VLDL1 and VLDL2) and ApoA-I and
apoA-II (isolated from HDL) were hydrolyzed, derivatized, and
subjected to gas chromatography mass spectrometer to measure
tracer leucine enrichment, as previously reported (13, 15).
Triglycerides were isolated from VLDL1 and VLDL2 frac-
tions and the tracer glycerol enrichment determined as previ-
ously reported (13).
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Modeling
Apoprotein enrichment data were modeled using SAAM-II
(The Epsilon Group) (16). The injected amount of [2H3]leucine
and [2H5]glycerol, the leucine and glycerol pool sizes in VLDL1
and VLDL2, and the enrichment curves of plasma leucine and
glycerol inVLDL1 andVLDL2 leucine and glycerolwere used for
amulticompartmentmodel that allowed simultaneousmodeling
of apoB and triglycerides kinetics as previously described (13)
and shown in Figure 1. ApoA-I modeling was performed using a
multicompartmentmodel as previously detailed (17). Briefly, the
apoA-I model includes a four-compartment subsystem (com-
partments 1–4) that describes plasma leucine kinetics. This sub-
system is connected to an intrahepatic delay compartment, com-
partment 5, that accounts for the time required for the synthesis
and secretion of apoA-I into plasma. Compartment 6 describes
the kinetics of apoA-I in the plasmaHDL fraction.ApoA-IImod-
eling was performed using the apoA-I model. The FCR was
equivalent to the loss from compartment 6, and the PR (mg/
kg1  d1)was calculated as the product of FCRand apoA-I (or
apoA-II) pool sizes.
Determination of liver and sc and visceral fat
Liver fat was determined using proton magnetic resonance
spectroscopy, and sc abdominal and visceral fat were measured
by magnetic resonance imaging as previously described (11).
Analytical procedures
Fasting plasma glucose, triglycerides,
HDL cholesterol, LDL cholesterol, and
plasma liver enzymes were determined
by standard procedures. Plasma apoA-I,
apoA-II, apoB, apoE, and adiponectin
weremeasured by an ELISA. Cholesteryl
ester transfer protein (CETP) activity
was determined as the capacity of a
plasma sample to promote the transfer of
radiolabeled cholesteryl esters ([3H]cho-
lesteryl ester) from [3H]cholesteryl ester
-HDL to apoB-containing lipoproteins
(18). Plasma phospholipid transfer pro-
tein (PLTP) activity was determined as
the capacity of aplasma sample to induce
the transfer of radiolabeled [14C]dipalmi-
toyl phosphatidylcholine from [14C]di-
palmitoyl phosphatidylcholine liposomes
to an excess of isolated HDL (19). Plasma
CETP and PLTP activity levels were re-
lated to the activity in a reference plasma
analyzed in each run and are expressed in
arbitrary units (AU).
Statistical analysis
Data are reported as mean SD. Sta-
tistical calculations were performed us-
ing theSPSS softwarepackage (SPSS Inc).
For continuous variables, a Kolmogo-
rov-Smirnov analysis was performed to
test for normality. The Pearson correla-
tion coefficients (r) were determined by
linear regression analysis. Statistical sig-
nificance of the correlation coefficients
was determined by the method of Fisher
and Yates. Multivariable analyses were performed by stepwise
linear regression, including into the model all the variables that
correlated in univariate analysis with P .10 and potential con-
founding factors such as age, gender, and study center. For mul-
tivariable analyses, data thatwere not normally distributedwere
log transformed. A two-tailed probability level of P  .05 was
accepted as statistically significant.
Results
Main characteristics of the abdominally obese
population
The clinical and biochemical characteristics of the pop-
ulation are shown in Table 1. The subjects were abdom-
inally obese, with amean BMI of 32.3 3.33 kg/m2, large
waist circumference (108 8 cm), and high insulin resis-
tance [mean homeostasis model assessment index of in-
sulin resistance (HOMA-IR) value of 3.14  1.88]. In
addition, the subjects also exhibited the typical dyslipide-
mia of the metabolic syndrome with high plasma triglyc-
erides and lowHDL cholesterol (HDL-C) concentrations.
Figure 1. Model for kinetic analysis. The model includes separate modules for leucine and
glycerol. The free leucine plasma kinetics is modeled by two pools (3 and 4) and a plasma
compartment (1), which interchange materials with an intracellular compartment (2).
Compartment 2 feeds the apolipoprotein B100 (apoB) synthetic machinery. For glycerol, the
plasma compartment (13) is connected to a pooling compartment (12) and feeds TG synthesis,
which consists of a fast pathway (14) and a slow pathway (21). The assembly of lipoprotein is
modeled by separate delays for apoB and TG. The plasma kinetics of apoB and TG is modeled by
a four-compartment hydrolysis chain, consisting of compartments 5, 6, 8, and 10 for apoB. Each
apoB compartment, i, has an associated TG compartment, i10, denoted as 15, 16, etc.
Compartments 5/15 and 6/16 are associated with VLDL1, together with a slowly decaying
compartment 7/17. Compartments 8/18 and 10/20 together with the slowly decaying compartment
9/19 form the VLDL2 module are shown. Solid arrows show the removal of whole particles and
dashed arrows show the removal of TG.
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Table 2 presents the kinetic data for apoA-I, apoA-II,
VLDL1-triglycerides (TGs), VLDL2-TGs, VLDL1-apoB,
and VLDL2-apoB of the abdominally obese population.
Correlations between main lipid, morphological,
and kinetic parameters
The correlation coefficients between the main lipid,
morphological, andkinetic parameters are shown inTable
3. apoA-I FCR was positively correlated with BMI, sc
fat, liver fat, HOMA-IR, plasma TGs, VLDL1-TGs and
VLDL1-apoB concentrations and negativelywithHDL-C,
HDL-C to apoA-I ratio, and HDL-C to apoA-II ratio. As
far as kinetic parameters are concerned, apoA-I FCR was
positively correlated with apoA-I production rate (PR),
apoA-II FCR, apoA-II PR, VLDL1-triglycerides PR, and
VLDL1-apoB PR. A borderline negative correlation was
observed between apoA-I FCR and VLDL1-TG indirect
FCR (r  0.247, P  .054).
Independent predictors for apoA-I catabolism
Because there was a strong correlation between apoA-I
FCR and apoA-I PR (r  0.900, P  .0001), we focused
on independent factors regulating apoA-I FCR by multi-
variable analyses.
First, we analyzed the morphological and biological
parameters that may predict apoA-I FCR. With this mul-
tivariable statistical model, liver fat and plasma TGs were
found to be independent predictor variables for apoA-I
FCR(Table 4, predictor variables,model 1).Whenplasma
TGs were replaced into the model, by VLDL1-TG con-
centration, both liver fat and VLDL1-TG concentration
were found to be independent predictor variables for
apoA-I FCR (Table 4, predictor variables,model 2).When
plasma TGs were replaced into the model, by VLDL1-
apoB concentration, both liver fat and VLDL1-apoB con-
centration were found to be independent predictor vari-
ables for apoA-I FCR (Table 4, predictor variables, model
3). The introduction of both VLDL1-TG and VLDL1-
apoB into the model gave identical results with those ob-
tained with model 3.
Next, we analyzed the morphological and biological
parameters that may be consequent variables of apoA-I
FCR.With thismultivariable statisticalmodel, theHDL-C
to apoA-I ratio and age were independently associated
with apoA-I FCR (Table 4, consequential variables).
We finally analyzed the kinetic parameters that may be
independently associated with apoA-I FCR. For this pur-
pose, we performed a multivariable analysis using all ki-
netic parameters that were correlated in univariate anal-
ysis with apoA-I FCR with a value of P  .10, except
apoA-I PR. apoA-I FCR was independently associated
with apoA-II FCR (P .0001), VLDL1-TG indirect FCR
(P  .001), and VLDL1-TG PR (P  .048) (Table 5).
Table 1. Clinical and Biochemical Characteristics of
the Abdominally Obese Individuals
Mean  SD
Age, y 51.5  8.1
Gender, M/F 50/12
BMI, kg/m2 32.3  3.33
Waist, cm 108  8
Hip, cm 110  7
Total fat, % 29.7  6.5
Liver fat, % 7.7  6.6
Visceral fat, kg 2.50  0.85
Subcutaneous fat, kg 27.02  6.92
Total cholesterol, mmol/L 4.77  0.72
TGs, mmol/L 1.98  0.71
LDL cholesterol, mmol/L 2.90  0.67
HDL cholesterol, mmol/L 0.97  0.15
VLDL1-TG, mg/dL 77  34
VLDL1-apoB, mg/dL 3.46  1.76
ApoA-I, mg/dL 118  14
ApoA-II, mg/dL 32  5
Fasting glucose, mmol/L 5.63  0.55
Plasma insulin, mU/L 12.21  6.74
HOMA-IR 3.14  1.88
CETP activity, AU 215  32
PLTP activity, AU 4948  1091
Abbreviations: BMI, body mass index; F, female; M, male.
Table 2. Kinetic Data for apoA-I, apoA-II, VLDL1-TG,
VLDL2-TG, VLDL1-apoB and VLDL2-apoB Metabolism in
the Abdominally Obese Individuals
Mean  SD [ranges]
ApoA-I FCR, pool  d1 0.29 0.07 [0.14–0.44]
ApoA-I PR, mg  kg1  d1 15.16 3.88 [8.11–23.53]
ApoA-II FCR, pool  d1 0.27 0.08 [0.14–0.54]
ApoA-II PR, mg  kg1  d1 3.86 1.37 [1.75–8.96]
VLDL1-TG direct FCR,
pool  d1
7.52 5.50 [1.06–25.33]
VLDL1-TG indirect FCR,
pool  d1
2.72 1.47 [0.69–7.94]
VLDL1-TG total FCR,
pool  d1
10.24 5.84 [2.71–30.81]
VLDL1-TG PR,
mg  kg1  d1
292.92 124.62 [121.96–625.75]
VLDL2-TG FCR, pool  d
1 14.02 6.79 [5.41–34.63]
VLDL2-TG PR,
mg  kg1  d1
110.51 53.30 [38.97–274.30]
VLDL1-apoB direct FCR,
pool  d1
2.90 2.67 [0.00–9.56]
VLDL1-apoB indirect FCR,
pool  d1
4.63 2.06 [1.14–10.07]
VLDL1-apoB total FCR,
pool  d1
7.53 3.22 [2.48–18.51]
VLDL1-apoB PR,
mg  kg1  d1
8.22 3.14 [3.60–16.45]
VLDL2-apoB FCR, pool  d
1 5.68 1.96 [2.57–11.90]
VLDL2-apoB PR,
mg  kg1  d1
7.04 2.76 [1.08–16.91]
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Together all three variables explained 64.7% of the vari-
ability in apoA-I FCR.
Liver fat, VLDL1 production, and apoA-I catabolism
Because liver fat was associated with both apoA-I FCR
andVLDL1production (VLDL1-TGPRandVLDL1-apoB
PR) and apoA-I FCRwas associated with VLDL1 produc-
tion (VLDL1-TG PR and VLDL1-apoB PR), we wanted to
test whether the association between liver fat and apoA-I
FCR was driven by VLDL1 production. After adjustment
for VLDL1-TG PR, liver fat was not significantly corre-
lated with apoA-I FCR.
Discussion
In a large multicenter in vivo kinetic study in abdominally
obese individuals, we show that kinetics of VLDL1 is an
important independent determinant for apoA-I FCR and
more precisely that apoA-I FCR is independently associ-
ated with both catabolism and production of VLDL1-TG.
In addition, we show an association between liver fat and
apoA-I FCR that is mostly mediated by the hepatic secre-
tion of VLDL1-TG.
Lipoprotein kinetic studies have shown thatVLDLs are
metabolically heterogeneous, with accumulating evidence
demonstrating that both the production and catabolismof
large VLDL1 and smaller VLDL2 are regulated indepen-
dently (10). The separate evaluation of VLDL1 and
VLDL2 metabolism is critical in the metabolic syndrome
or type 2 diabetes in which variations in plasma TG con-
centrations are mainly related to differences in VLDL1,
and hepatic overproduction of VLDLs is mainly due to
increased hepatic secretion of VLDL1 particles (11, 12).
To enhance our understanding of the pathways leading to
VLDL1 and VLDL2 and of the metabolic fate of these
particles, we used a multicompartmental mathematical
model that allows the kinetics of TGs and apoB100 in
VLDL1 and VLDL2 to be simultaneously assessed after a
bolus injection of glycerol and leucine. Using this model,
we have gained further insight into the relationship be-
tween the metabolism of TG-rich lipoproteins and the ca-
tabolism of HDL and to show that VLDL1 kinetics mod-
ulate HDL-apoA-I turnover.
We show that apoA-I FCR is independently associated
with both catabolism and production of VLDL1-TG, in-
dicating that kinetics of VLDL1 is an important indepen-
dent determinant for apoA-I FCR. Our data indicate that
VLDL1-TG indirect FCR, representing the catabolism of
VLDL1 particles mediated by lipoprotein lipase, is an im-
portant factor that is negatively associated with HDL
apoA-I FCR.Consistentwith these data, increase inVLDL
(or VLDL1) FCR induced by n-3 polyunsaturated fatty
acid supplementation or by rosuvastatin have been shown
to be significantly associated with reduction of HDL-
apoA-I catabolism (15, 20–22). Moreover, our data in-
dicate that VLDL1 PR is also an independent regulator of
HDL-apoA-I catabolism. This is in line with data from a
kinetic study performed in abdominally obese men that
showed that the reduction of VLDL production byweight
loss was accompanied by a significant decrease in HDL-
apoA-I catabolism (23). Hence, our data strongly suggest
that the hypercatabolism of HDL-apoA-I observed in
abdominal obesity may be the consequence of dysregu-
lated metabolism of VLDL1 particles including both in-
creased VLDL1 production and reduced VLDL1 catab-
olism. Increased production and reduced catabolism of
VLDL1 particles result in an expanded pool of VLDL1,
which are large triglyceride-rich lipoproteins. This may
promote CETP-mediated triglyceride enrichment of
HDL particles and, as a consequence, enhance HDL
catabolism (24).
We also newly demonstrate that liver fat, assessed by
protonmagnetic resonance spectroscopy, is a positive and
independent predictor of HDL apoA-I catabolism among
morphological and biological variables. However, vis-
ceral fat was not found to be associated with HDL apoA-I
FCR. Increased VLDL1-apoB or VLDL1-TG production
rate has been shown to be positively correlated with liver
fat (11). In our study, we showed that the correlation be-
tween liver fat and HDL apoA-I FCR was not significant
after adjustment forVLDL1-TGPR.This suggests that the
association between liver fat and apoA-I FCR is mostly
mediated by the hepatic production of VLDL1-TG.
When analyzing the consequent variables associated
with HDL apoA-I FCR, we found that HDL-C to apoA-I
ratio was negatively associated with apoA-I catabolism.
Thus, overcatabolism of HDL in abdominal obesity is as-
sociated with smaller size HDL particles with reduced
cholesterol content. This is in line with the negative cor-
relation between HDL particle size and apoA-I FCR pre-
viously reported (9). It is also consistent with increased
triglyceride transfer from VLDL to HDL mediated by
CETP that results in the formation of smaller triglyceride-
rich HDL particles that are rapidly catabolized by hepatic
lipase in insulin resistance.
In addition, we newly demonstrate an independent as-
sociation between apoA-I and apoA-II catabolism. In sev-
eral lowHDL cholesterol states, apoA-I FCR and apoA-II
FCR are modified to the same extent. For example, a par-
allel increase in apoA-I FCR and apoA-II FCR has been
reported in patients with primary HDL deficiency (25) as
well as in individualswith themetabolic syndrome (12). In
addition, the link between apoA-I and apoA-II catabolism
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Table 3. Pearson Correlation Coefficients in the 62 Abdominally Obese Individuals
Age, y BMI, kg/m2 Visceral Fat Subcutaneous Fat Liver Fat HOMA-IR TGs
Age, y
BMI, kg/m2 0.126
Visceral fat 0.035 0.461a
Subcutaneous fat 0.021 0.813b 0.310c
Liver fat 0.053 0.567b 0.390d 0.481b
HOMA-IR 0.173 0.490b 0.509b 0.469a 0.539b
TGs 0.040 0.385d 0.345d 0.246 0.353d 0.357d
HDL-C 0.042 0.164 0.148 0.012 0.50 0.187 0.312c
HDL-C/apoA-I 0.122 0.453a 0.340d 0.330d 0.413a 0.414a 0.595b
HDL-C/apoA-II 0.143 0.298c 0.309c 0.283c 0.199 0.385d 0.637b
VLDL1-TG 0.064 0.420
a 0.461a 0.188 0.335d 0.403d 0.826b
VLDL1-apoB 0.016 0.411a 0.300c 0.259c 0.355d 0.300c 0.574b
apoA-I pool 0.340d 0.486b 0.338c 0.474a 0.284c 0.117 0.266c
apoA-I FCR 0.125 0.410a 0.129 0.334d 0.427a 0.271c 0.422a
apoA-I PR 0.154 0.396d 0.031 0.367d 0.415a 0.235 0.434a
apoA-II pool 0.355d 0.435a 0.412a 0.471a 0.284c 0.248 0.380d
apoA-II FCR 0.158 0.310c 0.156 0.266c 0.307c 0.129 0.191
apoA-II PR 0.267c 0.336d 0.171 0.343d 0.329d 0.140 0.297c
VLDL1-TG PR 0.049 0.440
a 0.348d 0.509b 0.664b 0.377d 0.333d
VLDL2-TG PR 0.259
c 0.280c 0.442a 0.230 0.179 0.156 0.142
VLDL1-TG direct FCR 0.145 0.048 0.213 0.190 0.250 0.097 0.271
c
VLDL1-TG indirect FCR 0.153 0.086 0.031 0.018 0.143 0.147 0.537
b
VLDL1-TG total FCR 0.097 0.067 0.193 0.183 0.200 0.128 0.390
d
VLDL2-TG FCR 0.316
c 0.060 0.119 0.054 0.134 0.051 0.239
VLDL1-apoB PR 0.105 0.400
d 0.323c 0.431a 0.574b 0.322d 0.430d
VLDL2-apoB PR 0.166 0.271
c 0.335d 0.192 0.348d 0.165 0.255c
VLDL1-apoB direct FCR 0.112 0.005 0.232 0.197 0.122 0.053 0.080
VLDL1-apoB indirect FCR 0.021 0.204 0.122 0.093 0.163 0.275
c 0.573b
VLDL1-apoB total FCR 0.106 0.135 0.272
c 0.102 0.003 0.219 0.434a
VLDL2-apoB FCR 0.089 0.027 0.257
c 0.064 0.195 0.116 0.112
CETP activity 0.336# 0.028 0.091 0.009 0.081 0.177 0.033
PLTP activity 0.007 0.018 0.121 0.027 0.177 0.120 0.145
apoA-II
FCR
apoA-II
PR
VLDL1-TG
PR VLDL2-TG PR
VLDL1-TG
Direct FCR
VLDL1-TG
Indirect FCR
VLDL1-TG
Total FCR
Age, y
BMI, kg/m2
Visceral fat
Subcutaneous fat
Liver fat
HOMA-IR
TG
HDL-C
HDL-C/apoA-I
HDL-C/apoA-II
VLDL1-TG
VLDL1-apoB
apoA-I pool
apoA-I FCR
apoA-I PR
apoA-II pool
apoA-II FCR
apoA-II PR 0.915b
VLDL1-TG PR 0.361
d 0.331d
VLDL2-TG PR 0.267
c 0.283c 0.229
VLDL1-TG direct FCR 0.077 0.009 0.545
b 0.272
VLDL1-TG indirect FCR 0.209 0.156 0.181 0.491
b 0.107
VLDL1-TG total FCR 0.125 0.031 0.468
a 0.132 0.968b 0.353d
VLDL2-TG FCR 0.383
d 0.355d 0.054 0.648b 0.126 0.618b 0.037
VLDL1-apoB PR 0.244 0.255
c 0.758b 0.216 0.286c 0.286c 0.197
VLDL2-apoB PR 0.083 0.036 0.282
c 0.497b 0.099 0.003 0.103
VLDL1-apoB direct FCR 0.077 0.083 0.481
b 0.135 0.763b 0.020 0.723b
VLDL1-apoB indirect FCR 0.010 0.122 0.275
c 0.045 0.310c 0.690b 0.465a
VLDL1-apoB total FCR 0.058 0.010 0.189 0.094 0.772
b 0.452a 0.840b
VLDL2-apoB FCR 0.259
c 0.149 0.080 0.273c 0.138 0.292 0.056
CETP activity 0.143 0.197 0.083 0.057 0.247 0.039 0.242
PLTP activity 0.004 0.065 0.095 0.180 0.181 0.375d 0.265c
VLDL1-apoB data were derived from 58 subjects and VLDL1 TG kinetic data from 46 subjects.
a P  .001.
b P  .0001.
c P  .05.
d P  .01.
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Table 3. Continued
HDL-C HDL-C/apoA-I HDL-C/apoA-II VLDL1-TG VLDL1-apoB apoA-I Pool apoA-I FCR apoA-I PR apoA-II Pool
Age, y
BMI, kg/m2
Visceral fat
Subcutaneous fat
Liver fat
HOMA-IR
TGs
HDL-C
HDL-C/apoA-I 0.646b
HDL-C/apoA-II 0.560b 0.622b
VLDL1-TG 0.213 0.483
b 0.575b
VLDL1-apoB 0.105 0.326d 0.344d 0.706b
apoA-I pool 0.328d 0.056 0.100 0.287c 0.299c
apoA-I FCR 0.340d 0.512b 0.385d 0.443a 0.455a 0.223
apoA-I PR 0.029 0.380d 0.281c 0.414a 0.481b 0.206 0.900
apoA-II pool 0.247 0.087 0.460a 0.433a 0.326d 0.824b 0.177 0.279c
apoA-II FCR 0.150 0.292c 0.230 0.136 0.244 0.121 0.672b 0.612b 0.303c
apoA-II PR 0.226 0.226 0.352d 0.230 0.290c 0.123 0.606b 0.652b 0.580b
VLDL1-TG PR 0.205 0.480
b 0.305c 0.307c 0.287c 0.127 0.512b 0.404d 0.248
VLDL2-TG PR 0.065 0.268
c 0.291c 0.336d 0.064 0.325d 0.083 0.008 0.397d
VLDL1-TG direct FCR 0.098 0.020 0.121 0.458
a 0.253c 0.247 0.054 0.019 0.219
VLDL1-TG indirect FCR 0.083 0.195 0.181 0.518
b 0.480b 0.047 0.247 0.281c 0.015
VLDL1-TG total FCR 0.071 0.030 0.159 0.562
b 0.359d 0.221 0.012 0.089 0.202
VLDL2-TG FCR 0.058 0.051 0.021 0.085 0.108 0.293
c 0.053 0.017 0.275c
VLDL1-apoB PR 0.184 0.401
d 0.302c 0.437a 0.367d 0.081 0.422a 0.347d 0.191
VLDL2-apoB PR 0.242 0.307
c 0.193 0.360d 0.307c 0.068 0.190 0.088 0.038
VLDL1-apoB direct FCR 0.066 0.093 0.079 0.277
c 0.288c 0.104 0.075 0.094 0.073
VLDL1-apoB indirect FCR 0.002 0.247 0.330
d 0.640b 0.521b 0.211 0.224 0.292c 0.306c
VLDL1-apoB total FCR 0.056 0.081 0.277
c 0.613b 0.547b 0.222 0.082 0.109 0.256c
VLDL2-apoB FCR 0.161 0.129 0.027 0.067 0.056 0.036 0.059 0.073 0.117
CETP activity 0.177 0.215 0.106 0.140 0.072 0.205 0.076 0.124 0.149
PLTP activity 0.057 0.055 0.216 0.130 0.180 0.048 0.001 0.085 0.026
VLDL2-TG
FCR
VLDL1-apoB
PR
VLDL2-apoB
PR
VLDL1-apoB
Direct FCR
VLDL1-apoB
Indirect FCR
VLDL1-apoB
Total FCR
VLDL2-apoB
FCR
CETP
Activity
PLTP
Activity
Age, y
BMI, kg/m2
Visceral fat
Subcutaneous fat
Liver fat
HOMA-IR
TG
HDL-C
HDL-C/apoA-I
HDL-C/apoA-II
VLDL1-TG
VLDL1-apoB
apoA-I pool
apoA-I FCR
apoA-I PR
apoA-II pool
apoA-II FCR
apoA-II PR
VLDL1-TG PR
VLDL2-TG PR
VLDL1-TG direct FCR
VLDL1-TG indirect FCR
VLDL1-TG total FCR
VLDL2-TG FCR
VLDL1-apoB PR 0.120
VLDL2-apoB PR 0.021 0.546
b
VLDL1-apoB direct FCR 0.113 0.383
d 0.346d
VLDL1-apoB indirect FCR 0.204 0.223 0.197 0.095
VLDL1-apoB total FCR 0.044 0.176 0.162 0.771
b 0.561b
VLDL2-apoB FCR 0.625
b 0.065 0.323c 0.373d 0.322d 0.104
CETP activity 0.14 0.090 0.107 0.085 0.102 0.136 0.019
PLTP activity 264c 0.024 0.082 0.030 0.308c 0.172 0.160 0.23
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is also suggested by a study showing that apoA-I facilitates
hepatic lipase-mediated hydrolysis in apoA-II containing
HDL particles (26). Collectively, our data indicate a robust,
direct relationship between the catabolism of apoA-I and
apoA-II, consistent with the tight structural nexus of these
apoproteins in biogenesis and the disposal ofHDLparticles.
In the present study, we observe a very strong associ-
ation between apoAI FCR and apoAI PR that has previ-
Table 4. Mutivariable Analysis With apoA-I FCR as Dependent Variable (With Morphological and Biological Parameters)
Variables  t P Value r2 r2 Change
Predictor variables
Model 1
Liver fat 0.404 3.42 .001 0.265
TGs 0.361 3.07 .004 0.383 0.118
BMI 0.201 1.49 .142
Age, 0.146 1.31 .196
Subcutaneous fat 0.157 1.23 .223
Visceral fat 0.130 1.02 .311
HOMA-IR 0.072 0.54 .591
Gender 0.023 0.20 .840
Model 2
Liver fat 0.414 3.29 .002 0.265
VLDL1-TG 0.295 2.35 .023 0.342 0.077
BMI 0.217 1.50 .140
Subcutaneous fat 0.182 1.38 .175
Visceral fat 0.165 1.20 .235
Age 0.134 1.13 .262
HOMA-IR 0.098 0.68 .499
Gender 0.009 0.07 .941
Model 3
Liver fat 0.400 3.14 .003 0.265
VLDL1-apoB 0.307 2.42 .020 0.346 0.081
BMI 0.218 1.51 .136
Age 0.163 1.39 .171
Subcutaneous fat 0.161 1.21 .232
Visceral fat 0.087 0.66 .509
HOMA-IR 0.049 0.35 .726
Gender 0.034 0.28 .778
Consequential variables (age and
gender in the model)
HDL-C/apoA-I 0.593 5.49 <.0001 0.305
Age 0.248 2.29 .026 0.365 0.060
Gender 0.120 1.04 .301
HDL-C/apoA-II 0.035 0.24 .810
HDL-C 0.004 0.03 .975
apoA-I pool 0.002 0.02 .984
Abbreviations: , standardized coefficient; BMI, body mass index. Significant parameter values are shown in bold and italic.
For predictor variables, model 1, total r2  0.383. For predictor variables, model 2, total r2  0.342. For predictor variables, model 3, total r2 
0.346. For consequential variables, total r2  0.365. Age and gender in the model.
Table 5. Mutivariable Analysis With apoA-I FCR as Dependent Variable (With VLDL Subspecies and apoA-II Kinetic
Parameters)
Variables  t P Value r2 r2 Change
ApoA-II FCR 0.667 6.32 <.0001 0.448
VLDL1-TG indirect FCR 0.357 3.58 .001 0.610 0.162
VLDL1-TG PR 0.213 2.04 .048 0.647 0.037
Study center 0.193 1.66 .104
ApoA-II PR 0.366 1.41 .166
Age 0.115 1.16 .252
BMI 0.121 1.09 .280
VLDL1-apoB indirect FCR 0.155 1.09 .280
Gender 0.059 0.58 .560
VLDL1-apoB PR 0.060 0.42 .676
Abbreviations: : standardized coefficient; BMI, body mass index. Total r2  0.647 (age, gender, and center in the model). Significant parameter
values are shown in bold and italic.
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ously been reported (8). Although a direct mathematical
link exists between PR and FCR because PR is calculated
with FCRas a variable, we cannot exclude balancing feed-
back mechanisms between apoAI FCR and apoAI PR.
However, this hypothesis needs further investigation.
We consider that the strong association between
VLDL1 kinetics and HDL-apoA-I catabolism has impor-
tant implications. For instance, in conditions of abdomi-
nal obesity, the reduction of hepatic secretion of VLDL1,
and/or an increase in the catabolism of VLDL1 by weight
loss and physical exercise will regulate the catabolism of
HDL, resulting in a long-term increase in HDL choles-
terol. In addition, an increase in HDL-apoA-I catabolism
can result indysfunctional, proatherogenicHDLparticles,
with an impaired capacity to effect cellular cholesterol
efflux and a reduced antioxidative and anti-inflammatory
properties (27). Hence, lifestyle interventions, such as
weight regulation and aerobic exercise, may correct HDL
overcatabolismanddysfunctionality by decreasing the he-
patic secretion of the VLDL1 subspecies.
Our investigation has the limitations of a cross-sec-
tional design. We studied more men than women and
might have missed gender differences in the relationship
between the kinetics of VLDL subspecies and HDL
apoA-I. We did not study the kinetics of HDL subspecies
or the turnover of LpA-I and LpA-I:A-II particles. This
requires further investigation but would expect that an
expanded VLDL1 pool size would result in accelerate ca-
tabolism in all HDL particles, with a preferential reduc-
tion in smaller size particles (12).
In conclusion, we demonstrated that VLDL1 is an im-
portant independent determinant for apoA-I FCR and
more precisely that apoA-I FCR is independently associ-
ated with both catabolism and production of VLDL1-TG.
In addition, we show an association between liver fat and
apoA-I FCR that is mostly mediated by VLDL1-TG pro-
duction. These data indicate that, in abdominal obesity,
dysfunctional VLDL1 metabolism is an important modu-
lator of HDL apoA-I catabolism.
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